

# Horea Rus

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11324229/publications.pdf>

Version: 2024-02-01

76  
papers

3,215  
citations

126907

33  
h-index

161849

54  
g-index

76  
all docs

76  
docs citations

76  
times ranked

3524  
citing authors

#	ARTICLE	IF	CITATIONS
1	Membrane attack by complement: the assembly and biology of terminal complement complexes. <i>Immunologic Research</i> , 2011, 51, 45-60.	2.9	242
2	The Role of the Complement System in Innate Immunity. <i>Immunologic Research</i> , 2005, 33, 103-112.	2.9	192
3	The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 11094-11099.	7.1	172
4	Sublytic C5b-9 induces proliferation of human aortic smooth muscle cells. <i>Atherosclerosis</i> , 1999, 142, 47-56.	0.8	109
5	C5b-9 Terminal Complement Complex Protects Oligodendrocytes from Death by Regulating Bad Through Phosphatidylinositol 3-Kinase/Akt Pathway. <i>Journal of Immunology</i> , 2001, 167, 2305-2311.	0.8	105
6	RGC-32 Increases p34CDC2 Kinase Activity and Entry of Aortic Smooth Muscle Cells into S-phase. <i>Journal of Biological Chemistry</i> , 2002, 277, 502-508.	3.4	101
7	The Role of Complement Activation in Atherosclerosis. <i>Immunologic Research</i> , 2004, 30, 073-080.	2.9	92
8	Complement activation and atherosclerosis. <i>Molecular Immunology</i> , 1999, 36, 949-955.	2.2	86
9	Molecular Cloning and Characterization of RGC-32, a Novel Gene Induced by Complement Activation in Oligodendrocytes. <i>Journal of Biological Chemistry</i> , 1998, 273, 26977-26981.	3.4	85
10	The role of complement system in adipose tissue-related inflammation. <i>Immunologic Research</i> , 2016, 64, 653-664.	2.9	85
11	C5b-9-induced Endothelial Cell Proliferation and Migration Are Dependent on Akt Inactivation of Forkhead Transcription Factor FOXO1. <i>Journal of Biological Chemistry</i> , 2006, 281, 19009-19018.	3.4	81
12	The Role of C5b-9 Terminal Complement Complex in Activation of the Cell Cycle and Transcription. <i>Immunologic Research</i> , 2005, 31, 37-46.	2.9	69
13	RGC-32 Mediates Transforming Growth Factor- $\beta$ -induced Epithelial-Mesenchymal Transition in Human Renal Proximal Tubular Cells. <i>Journal of Biological Chemistry</i> , 2009, 284, 9426-9432.	3.4	66
14	Complement C5 in Experimental Autoimmune Encephalomyelitis (EAE) Facilitates Remyelination and Prevents Gliosis. <i>American Journal of Pathology</i> , 2003, 163, 1069-1080.	3.8	65
15	Mechanisms of Signal Transduction Activated by Sublytic Assembly of Terminal Complement Complexes on Nucleated Cells. <i>Immunologic Research</i> , 2001, 24, 191-200.	2.9	61
16	SIRT1 is decreased during relapses in patients with multiple sclerosis. <i>Experimental and Molecular Pathology</i> , 2014, 96, 139-148.	2.1	59
17	Response gene to complement 32 is required for C5b-9 induced cell cycle activation in endothelial cells. <i>Experimental and Molecular Pathology</i> , 2009, 86, 87-94.	2.1	57
18	The complement system as a biomarker of disease activity and response to treatment in multiple sclerosis. <i>Immunologic Research</i> , 2017, 65, 1103-1109.	2.9	56

#	ARTICLE	IF	CITATIONS
19	Potassium channels Kv1.3 and Kv1.5 are expressed on blood-derived dendritic cells in the central nervous system. <i>Annals of Neurology</i> , 2006, 60, 118-127.	5.3	55
20	The complement system in central nervous system diseases. <i>Autoimmunity</i> , 2006, 39, 395-402.	2.6	54
21	Oligodendrocyte cell death in pathogenesis of multiple sclerosis: Protection of oligodendrocytes from apoptosis by complement. <i>Journal of Rehabilitation Research and Development</i> , 2006, 43, 123.	1.6	54
22	C5b-9 Terminal Complex Protects Oligodendrocytes from Apoptotic Cell Death by Inhibiting Caspase-8 Processing and Up-Regulating FLIP. <i>Journal of Immunology</i> , 2006, 176, 3173-3180.	0.8	54
23	Overexpression of RGC-32 in colon cancer and other tumors. <i>Experimental and Molecular Pathology</i> , 2005, 78, 116-122.	2.1	52
24	Role of SIRT1 in autoimmune demyelination and neurodegeneration. <i>Immunologic Research</i> , 2015, 61, 187-197.	2.9	52
25	The role of complement activation in atherogenesis: the first 40 years. <i>Immunologic Research</i> , 2016, 64, 1-13.	2.9	52
26	Role of response gene to complement 32 in diseases. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2008, 56, 115-122.	2.3	46
27	Terminal complement complexes concomitantly stimulate proliferation and rescue of Schwann cells from apoptosis. , 2000, 30, 187-198.		43
28	Terminal complement complexes induce cell cycle entry in oligodendrocytes through mitogen activated protein kinase pathway. <i>Immunopharmacology</i> , 1997, 38, 177-187.	2.0	42
29	Effects of Complement C5 on Apoptosis in Experimental Autoimmune Encephalomyelitis. <i>Journal of Immunology</i> , 2004, 172, 5702-5706.	0.8	41
30	Epigenetic modifications induced by RGC-32 in colon cancer. <i>Experimental and Molecular Pathology</i> , 2010, 88, 67-76.	2.1	41
31	Dual role of Response gene to complement-32 in multiple sclerosis. <i>Experimental and Molecular Pathology</i> , 2013, 94, 17-28.	2.1	41
32	C5b-9 complement complex in autoimmune demyelination and multiple sclerosis: Dual role in neuroinflammation and neuroprotection. <i>Annals of Medicine</i> , 2005, 37, 97-104.	3.8	35
33	Complement activation in diabetic ketoacidosis brains. <i>Experimental and Molecular Pathology</i> , 2006, 80, 283-288.	2.1	35
34	Complement activation in autoimmune demyelination: Dual role in neuroinflammation and neuroprotection. <i>Journal of Neuroimmunology</i> , 2006, 180, 9-16.	2.3	35
35	RGC-32 is a novel regulator of the T-lymphocyte cell cycle. <i>Experimental and Molecular Pathology</i> , 2015, 98, 328-337.	2.1	35
36	Both apoptosis and complement membrane attack complex deposition are major features of murine acute graft-vs.-host disease. <i>Experimental and Molecular Pathology</i> , 2005, 79, 136-145.	2.1	34

#	ARTICLE	IF	CITATIONS
37	Neuroinflammatory response of the choroid plexus epithelium in fatal diabetic ketoacidosis. <i>Experimental and Molecular Pathology</i> , 2007, 83, 65-72.	2.1	34
38	Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in cancer. <i>Immunologic Research</i> , 2013, 56, 109-121.	2.9	34
39	Tyrosine phosphorylation and activation of Janus kinase 1 and STAT3 by sublytic C5b-9 complement complex in aortic endothelial cells. <i>Immunopharmacology</i> , 1999, 42, 187-193.	2.0	33
40	C5b-9 terminal complement complex assembly on apoptotic cells in human arterial wall with atherosclerosis. <i>Experimental and Molecular Pathology</i> , 2004, 76, 17-23.	2.1	33
41	IL-21 Promotes Lupus-like Disease in Chronic Graft-versus-Host Disease through Both CD4 T Cell- and B Cell-Intrinsic Mechanisms. <i>Journal of Immunology</i> , 2012, 189, 1081-1093.	0.8	33
42	Pathogenic T cells in murine lupus exhibit spontaneous signaling activity through phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways. <i>Arthritis and Rheumatism</i> , 2003, 48, 1071-1079.	6.7	31
43	TRAIL, DR4 and DR5 are upregulated in kidneys from patients with lupus nephritis and exert proliferative and proinflammatory effects. <i>Clinical Immunology</i> , 2009, 132, 32-42.	3.2	29
44	SIRT1 as a potential biomarker of response to treatment with glatiramer acetate in multiple sclerosis. <i>Experimental and Molecular Pathology</i> , 2017, 102, 191-197.	2.1	27
45	The Complement System in Central Nervous System Diseases. <i>Immunologic Research</i> , 2001, 24, 79-86.	2.9	26
46	Localization of the terminal C5b-9 complement complex in the human aortic atherosclerotic wall. <i>Immunology Letters</i> , 1985, 10, 109-114.	2.5	24
47	Dendritic cells are abundant in non-lesional gray matter in multiple sclerosis. <i>Experimental and Molecular Pathology</i> , 2007, 83, 198-206.	2.1	24
48	C5b-9-activated, Kv1.3 channels mediate oligodendrocyte cell cycle activation and dedifferentiation. <i>Experimental and Molecular Pathology</i> , 2011, 91, 335-345.	2.1	22
49	Neuroprotective effects of the complement terminal pathway during demyelination: Implications for oligodendrocyte survival. <i>Journal of Neuroimmunology</i> , 2009, 213, 3-11.	2.3	21
50	Complement C5 regulates the expression of insulin-like growth factor binding proteins in chronic experimental allergic encephalomyelitis. <i>Journal of Neuroimmunology</i> , 2008, 203, 94-103.	2.3	18
51	Phosphorylated SIRT1 as a biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis. <i>Experimental and Molecular Pathology</i> , 2018, 105, 175-180.	2.1	18
52	FLT-3 expression and function on microglia in multiple sclerosis. <i>Experimental and Molecular Pathology</i> , 2010, 89, 109-116.	2.1	17
53	RGC-32 is expressed in the human atherosclerotic arterial wall: Role in C5b-9-induced cell proliferation and migration. <i>Experimental and Molecular Pathology</i> , 2016, 101, 221-230.	2.1	17
54	Effects of Membrane Attack Complex of Complement on Apoptosis in Experimental Autoimmune Encephalomyelitis. <i>Annals of the New York Academy of Sciences</i> , 2003, 1010, 530-533.	3.8	16

#	ARTICLE	IF	CITATIONS
55	RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis. <i>Experimental and Molecular Pathology</i> , 2015, 99, 498-505.	2.1	16
56	RGC-32 regulates reactive astrocytosis and extracellular matrix deposition in experimental autoimmune encephalomyelitis. <i>Immunologic Research</i> , 2018, 66, 445-461.	2.9	16
57	Role of C5b-9 and RGC-32 in Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 1054.	4.8	16
58	CTL-Promoting Effects of IL-21 Counteract Murine Lupus in the Parentâ†’F1 Graft-versus-Host Disease Model. <i>Journal of Immunology</i> , 2016, 196, 1529-1540.	0.8	13
59	C5b-9 Complement Complex in Autoimmune Demyelination: Dual Role in Neuroinflammation and Neuroprotection. , 2006, 586, 139-151.		12
60	B-cells and humoral immunity in multiple sclerosis. Implications for therapy. <i>Immunologic Research</i> , 2008, 40, 224-234.	2.9	12
61	Sublytic terminal complement attack induces c-fos transcriptional activation in myotubes. <i>Journal of Neuroimmunology</i> , 2003, 142, 58-66.	2.3	11
62	JNK1 activation mediates C5b-9-induced P0 mRNA instability and P0 gene expression in Schwann cells. <i>Journal of the Peripheral Nervous System</i> , 2006, 11, 77-87.	3.1	11
63	RGC-32 and diseases: the first 20Âyears. <i>Immunologic Research</i> , 2019, 67, 267-279.	2.9	11
64	Histone Deacetylase SIRT1 Mediates C5b-9-Induced Cell Cycle in Oligodendrocytes. <i>Frontiers in Immunology</i> , 2020, 11, 619.	4.8	10
65	Complement System in Central Nervous System Disorders. , 1998, , 499-525.		10
66	Inflammatory Response in Unstable Angina. <i>Circulation</i> , 1999, 100, e98.	1.6	7
67	Regulator of Cell Cycle Protein (RGCC/RGC-32) Protects against Pulmonary Fibrosis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2022, 66, 146-157.	2.9	6
68	Intracerebral matrix metalloproteinase 9 in fatal diabetic ketoacidosis. <i>Experimental and Molecular Pathology</i> , 2019, 108, 97-104.	2.1	5
69	Markers of immune-mediated inflammation in the brains of young adults and adolescents with type 1 diabetes and fatal diabetic ketoacidosis. Is there a difference?. <i>Experimental and Molecular Pathology</i> , 2017, 102, 505-514.	2.1	4
70	RGC-32 Regulates Generation of Reactive Astrocytes in Experimental Autoimmune Encephalomyelitis. <i>Frontiers in Immunology</i> , 2020, 11, 608294.	4.8	4
71	JNK and phosphorylated Bcl-2 predict multiple sclerosis clinical activity and glatiramer acetate therapeutic response. <i>Clinical Immunology</i> , 2020, 210, 108297.	3.2	3
72	RGC-32â€² dual role in smooth muscle cells and atherogenesis. <i>Clinical Immunology</i> , 2022, 238, 109020.	3.2	3

#	ARTICLE	IF	CITATIONS
73	Association of Complement Inhibitors With Connective Tissue Matrix in Atherosclerotic Lesions. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 1478-1478.	2.4	2
74	RGC-32 Acts as a Hub to Regulate the Transcriptomic Changes Associated With Astrocyte Development and Reactive Astrocytosis. <i>Frontiers in Immunology</i> , 2021, 12, 705308.	4.8	1
75	Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1729-1743.	3.0	1
76	Letter by Rus et al Regarding Article, "RGC-32 (Response Gene to Complement 32) Deficiency Protects Endothelial Cells From Inflammation and Attenuates Atherosclerosis", <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, e96.	2.4	0